Title: First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Hepatobiliary Cancers and Other Solid Tumors

Journal: Targeted Oncology

Authors: James J. Harding • Christiane Jungels • Jean-Pascal Machiels • David C. Smith • Chris Walker • Tao Ji • Ping Jiang • Xin Li • Ekaterine Asatiani • Eric Van Cutsem • Ghassan K. Abou-Alfa

Corresponding author: James J. Harding, MD (E-mail: Hardinj1@mskcc.org)

Online Supplementary Table 3 Summary of pharmacokinetic parameters for INCB062079 at steady-state (Cycle 1, Day 15)

Treatment	Patients, n	$C_{max,ss}$, nM	T_{max}, h	$t_{½}$, h	$C_{min,ss}$, nM	$AUC_{ss,0-\tau}$, h•nM	CL_{ss}/F, L/h	V_z/F , L
10 mg QD	3	954 ± 238	1.05	6.49 ± 0.518	68.9 ± 15.0	6990 ± 1180	3.39 ± 0.535	31.5 ± 2.85
		935 (25.1)	(1.05–1.88)	6.48 (7.83)	67.8 (22.5)	6930 (16.5)	3.36 (16.5)	31.4 (9.09)
10 mg BID	5	709 ± 190	2.13	5.21 ± 0.969	237 ± 73.4	5730 ± 1180	4.23 ± 0.994	30.9 ± 3.97
		690 (25.6)	(1.00–6.67)	5.14 (19.5)	225 (39.8)	5620 (22.4)	4.14 (22.4)	30.7 (13.8)
10 mg BID[a]	4	1080 ± 348	2.59	7.68 ± 1.51	440 ± 147	8150 ± 2200	3.07 ± 1.07	32.6 ± 5.38
		1030 (40.3)	(0.50–4.03)	7.57 (20.2)	415 (43.5)	7890 (32.0)	2.95 (32.0)	32.3 (16.6)
15 mg BID	3	1090 ± 124	2.05	5.20 ± 1.35	274 ± 111	7070 ± 1290	5.04 ± 0.867	37.0 ± 7.18
		1080 (11.1)	(0.80–2.13)	5.07 (29.1)	258 (47.0)	7000 (17.9)	4.99 (17.9)	36.5 (19.3)
15 mg BID [a]	2	1980, 1290 [b]	1.02, 2.15 [b]	6.06, 13.1[b]	488, 770[b]	12800, 12100[b]	2.74, 2.89†	23.9, 54.8†

Values are presented in the format of mean ± SD and geometric mean (CV%) except for T_{max} (reported as median [range]) and the last row of the table.

[a]Patients enrolled after a protocol amendment requiring all newly enrolled patients to have a C4 concentration <40.9 ng/mL and to take a prophylactic bile acid sequestrant for the prevention of diarrhea while receiving INCB062079 treatment. [b]Because statistical summary was not possible for pharmacokinetic parameters with only two patients, individual patient data are shown for the two patients instead.

$AUC_{ss,0-\tau}$ area under the plasma concentration-time curve over one dose interval at steady-state (τ = 12 hours for BID dosing and 24 hours for QD dosing), *BID* twice daily, CL_{ss}/F apparent clearance at steady-state, $C_{max,ss}$ maximum observed plasma concentration at steady-state, $C_{min,ss}$ minimum observed plasma concentration at steady-state, *CV* coefficient of variation, *QD* once daily, *SD* standard deviation, $t_{½}$ terminal half-life, T_{max} time to maximum observed plasma concentration, V_z/F apparent volume of distribution.